Ophthalmic Pharmacology: Glaucoma Drops, Ocular Steroids and Anti-VEGF Drugs

Evidence and references reviewed: 10 November 2026.

Ophthalmic medicines treat different parts of the eye through different routes. A glaucoma drop, an ocular-surface lubricant and an intravitreal retinal treatment are not interchangeable. Local administration also does not eliminate systemic risk: ophthalmic timolol can cause clinically important beta-blockade outside the eye.1,2,3,4

Ophthalmic pharmacokinetics: why drops can have systemic effects

Topical eye drops first encounter the tear film, corneal epithelium and conjunctiva. A substantial part of an instilled dose may drain through the nasolacrimal system into the nasal mucosa, where systemic absorption can occur. For example, ophthalmic timolol may cause bradycardia or bronchospasm in susceptible patients even though it is administered as a drop. Punctal occlusion and gentle eyelid closure can help reduce nasolacrimal drainage and systemic exposure.4,9

Ocular drug selection depends on whether the target is the aqueous outflow pathways, the ocular surface, the anterior segment or the retina. Large systemic doses cannot replace targeted intraocular delivery, and ocular dose units, drop concentration and intravitreal injection dose are not interchangeable.

Lowering intraocular pressure

Glaucoma drugs reduce aqueous-humor production, improve drainage, or do both. Selection depends on pressure control, tolerance and the possible need for laser or surgery.1

Class and examples Main action
Prostaglandin analogues: latanoprost, travoprost Increase aqueous outflow.1
Beta blockers: timolol, betaxolol Reduce aqueous production.1
Alpha-adrenergic agonists: brimonidine, apraclonidine Reduce aqueous production; individual agents can also affect outflow.1
Carbonic anhydrase inhibitors: dorzolamide, brinzolamide Reduce aqueous production.1
Rho kinase inhibitor: netarsudil Improves aqueous drainage.1
Cholinergic agent: pilocarpine Facilitates aqueous drainage.1

Timolol is nonselective, not beta-1 selective. Its ophthalmic label contraindicates use with asthma or a history of asthma, severe COPD, sinus bradycardia, second- or third-degree atrioventricular block, overt cardiac failure or cardiogenic shock. Systemic beta blockers and some cardiac drugs can increase adverse effects. Review cardiopulmonary history and other medicines before prescribing.4

2025 AAO glaucoma practice pattern, published in 2026

The American Academy of Ophthalmology’s primary open-angle glaucoma Preferred Practice Pattern, approved in September 2025 and published in February 2026, identifies prostaglandin analogues as the most frequently prescribed initial topical drugs because they effectively lower intraocular pressure with once-daily dosing. However, selective laser trabeculoplasty (SLT) is another appropriate initial treatment option for selected patients, particularly when drop adherence, cost or preferences are concerns.10

Lowering pressure reduces the risk of glaucomatous damage but does not reverse established optic-nerve injury. Target pressure is individualized according to optic-nerve findings, visual fields, baseline pressure, risk and progression. Glaucoma management may require visual-field testing, optic-nerve imaging, medicine adjustment, laser or surgery; no one pressure target or drop is best for everyone.

Comparison of glaucoma drug classes

Class Mechanism Common adverse effects or contraindications
Prostaglandin analogues (latanoprost, travoprost) Increase uveoscleral and other outflow pathways. Conjunctival redness, eyelash growth, iris/skin pigment changes.
Beta blockers (timolol) Reduce ciliary-body aqueous secretion via beta-adrenergic blockade. Bradycardia, heart block and bronchospasm; contraindicated with asthma for timolol.
Alpha-2 agonists (brimonidine) Reduce aqueous production and may increase outflow. Allergic conjunctivitis, systemic drowsiness; age-specific pediatric cautions.
Carbonic anhydrase inhibitors (dorzolamide, brinzolamide) Suppress carbonic anhydrase in ciliary epithelium and decrease bicarbonate-driven aqueous formation. Burning, taste disturbance, sulfonamide-related cautions.
Rho-kinase inhibitor (netarsudil) Reduces resistance to trabecular aqueous outflow. Conjunctival hyperemia, corneal verticillata in some patients.
Cholinergic agonist (pilocarpine) Contracts ciliary muscle and increases trabecular drainage in selected conditions. Brow ache, induced myopia, poor night vision and rare retinal risks.

Betaxolol is relatively beta-1 selective, but that does not eliminate respiratory risk. Timolol is nonselective (beta-1/beta-2) and should not be treated as safe in a patient with asthma merely because it is administered into the eye.4,10

Pupil dilation: distinguish receptor mechanisms

Tropicamide is anticholinergic; phenylephrine is an alpha-1 adrenergic agonist. Both contribute to pupil dilation, but phenylephrine must not be classified as an antimuscarinic. Concentrations and doses depend on the product and procedure. Diagnostic dilation regimens should not be repurposed as routine self-treatment.5

Inflammation and corticosteroids

Prednisolone acetate and other ocular corticosteroids treat appropriate inflammatory conditions under supervision. They can elevate intraocular pressure, contribute to posterior subcapsular cataract, delay healing and mask or worsen infection. PRED FORTE labelling calls for routine pressure monitoring when treatment continues for ten days or longer. These are important warnings, but not a universal boxed warning for every steroid eye drop.6

An undiagnosed red eye should not automatically receive a steroid-containing drop. Infection and inflammation must be distinguished, particularly when the cornea may be involved. Eye pain, sudden visual change, vision loss or injury warrants urgent assessment.6,7

Eye emergencies: when not to use routine drops

Sudden severe unilateral eye pain, a red eye with blurred vision, headache, halos around lights and nausea/vomiting can suggest acute angle-closure glaucoma, requiring emergency ophthalmic treatment. Sudden vision loss, a chemical injury, a penetrating injury, severe photophobia or a painful contact-lens-associated red eye also requires urgent evaluation.7

Corneal infection is particularly important in contact-lens users. An unsupervised steroid drop can worsen or mask certain infections, including herpes simplex keratitis or fungal disease. Patients should not use leftover steroid–antibiotic combinations for an undiagnosed red eye; accurate examination and, when needed, appropriate microbiology guide therapy.

Dry-eye therapy

Artificial tears are commonly used for mild dry eye; lubricating gels and ointments are other options. Persistent disease may require prescription cyclosporine or lifitegrast and measures directed at the cause. Persistent symptoms merit reassessment rather than indefinite switching between over-the-counter products. Dry-eye and glaucoma medicines serve different purposes.2

Dry-eye pharmacology and formulation considerations

Artificial tears provide temporary lubrication, with formulations such as carboxymethylcellulose, hyaluronic acid, polyethylene glycol or other polymers. Preservative-free products may be better tolerated when drops are needed frequently or ocular surface sensitivity is substantial. Cyclosporine inhibits calcineurin-mediated inflammation, while lifitegrast interferes with lymphocyte function-associated antigen 1 (LFA-1) signaling and T-cell activation. These prescription products are anti-inflammatory treatments for selected dry-eye disease, not instantaneous tears with identical onset or response.2

Before escalating prescription therapy, assess blepharitis/meibomian gland dysfunction, exposure, allergies, environment, systemic medicines, contact-lens use and other ocular disease. A persistent gritty feeling with significant pain or visual impairment requires evaluation rather than indefinitely changing lubricants.

Retinal disease and intravitreal treatment

Anti-VEGF agents target vascular endothelial growth factor signalling to reduce abnormal vascular growth or leakage. They are used for conditions including neovascular age-related macular degeneration and diabetic macular edema. Ranibizumab and aflibercept are examples. Eye specialists administer treatment, often through repeated intravitreal injections. Ordinary topical steroid drops are not interchangeable with retinal injection regimens.3

Intravitreal bevacizumab is an established off-label treatment: Avastin was approved for cancer, and its use in the eye is not an FDA-approved ocular indication. This distinction remains relevant even when clinical evidence supports use.8

Intravitreal anti-VEGF: the indication determines follow-up

VEGF-A drives abnormal neovascular growth and vascular permeability. Intravitreal ranibizumab, aflibercept, faricimab and selected other agents reduce leakage or neovascular activity in diseases such as neovascular age-related macular degeneration, diabetic macular edema or retinal vein occlusion. Product molecular targets, injection intervals and indications vary, and some drugs also target angiopoietin-2. Bevacizumab ocular use remains off label in the US in many circumstances despite substantial evidence and use.3,8

Rare but serious post-injection complications include endophthalmitis, retinal detachment and intraocular pressure changes. Severe eye pain, rapidly worsening vision, significant redness or new floaters after an injection warrant immediate ophthalmic contact. Retinal treatment requires serial visual and anatomical assessments, not a generic one-injection cure.

Administration is part of treatment

  • Wash hands and avoid touching the bottle tip to the eye or surrounding surfaces.9
  • After instilling the prescribed drop, gently close the eyelids and press near the inner corner for one to two minutes, or as instructed, to reduce drainage into the nose.9
  • Allow at least five minutes between different topical ophthalmic medicines unless product instructions specify otherwise.4
  • Check formulation-specific instructions, including shaking suspensions and removing or replacing contact lenses.6,4

Correct diagnosis, route, formulation and follow-up determine safe use. New pain or worsening vision requires review rather than simply adding more drops.7

Practical eye-drop administration checklist

  1. Confirm the eye, strength, formulation and schedule before instillation. Left/right errors and confusing a solution with a suspension can lead to treatment failure.
  2. Wash hands and avoid touching the nozzle to eyelid, lashes or skin.
  3. Instill the prescribed number of drops, gently close the eye, and use punctal occlusion when instructed.
  4. Separate different eye drops by at least five minutes unless product-specific guidance differs; ointments are usually administered after drops.
  5. Follow contact-lens restrictions, product storage and expiry after opening (especially preservative-free formulations).
  6. Attend intraocular pressure, optic nerve or retinal follow-up as needed; symptom improvement alone does not prove glaucoma is controlled.

Frequently asked questions

Can glaucoma eye drops affect the heart or lungs?

Yes. Timolol can be systemically absorbed and cause bradycardia or bronchospasm in susceptible patients.4

Are prostaglandin analogues often first-line glaucoma drops?

Yes, under the 2025 AAO practice pattern published in 2026; SLT is another important selected first-line approach.10

Is every red eye safe to treat with steroids?

No. An undiagnosed corneal infection may worsen with unsupervised corticosteroids.

Is bevacizumab FDA-approved specifically for eye injections?

No. Ophthalmic bevacizumab use is off label in the United States, even though evidence may support it in selected diseases.8

Can punctal occlusion reduce drug drainage?

Yes. It helps limit nasolacrimal drainage of topical medicines when performed correctly.9

References

  1. National Eye Institute. Glaucoma medicines [Internet] [cited 2026 Nov 10]. Available from: https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/glaucoma/glaucoma-medicines
  2. National Eye Institute. Dry eye [Internet] [cited 2026 Nov 10]. Available from: https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/dry-eye
  3. National Eye Institute. Injections to treat eye conditions [Internet] [cited 2026 Nov 10]. Available from: https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/diabetic-retinopathy/injections-treat-eye-conditions
  4. National Library of Medicine. Timolol maleate ophthalmic solution: prescribing information. DailyMed [Internet] [cited 2026 Nov 10]. Available from: https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b686bbad-1ef7-4b94-a316-4d182a40b89a&type=display
  5. National Library of Medicine. MYDCOMBI (tropicamide and phenylephrine): prescribing information. DailyMed [Internet] [cited 2026 Nov 10]. Available from: https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dbff7eeb-a16a-4106-ae5e-4effdd33cc45
  6. National Library of Medicine. PRED FORTE (prednisolone acetate ophthalmic suspension): prescribing information. DailyMed [Internet] [cited 2026 Nov 10]. Available from: https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=00a5aa88-e361-4ea7-8922-530c738b726e
  7. American Academy of Ophthalmology. Eye symptoms [Internet] [cited 2026 Nov 10]. Available from: https://www.aao.org/eye-health/symptoms-list
  8. American Academy of Ophthalmology. What is Avastin? [Internet] [cited 2026 Nov 10]. Available from: https://www.aao.org/eye-health/drugs/avastin
  9. American Academy of Ophthalmology. How to put in eye drops [Internet] [cited 2026 Nov 10]. Available from: https://www.aao.org/eye-health/treatments/how-to-put-in-eye-drops
  10. Gedde SJ, Bowden EC, Challa P, et al. Primary open-angle glaucoma Preferred Practice Pattern. Ophthalmology. Published online 9 Feb 2026. doi:10.1016/j.ophtha.2025.12.029. American Academy of Ophthalmology.

⚠️ Medical Disclaimer

This article is intended for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.

The information provided here is based on current scientific literature and established pharmacological principles. However, medical knowledge evolves continuously, and individual patient responses to medications may vary. Healthcare professionals should always use their clinical judgment when applying this information to patient care.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *